STATHMIN — Stathmin-1 (Oncoprotein 18)
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">STATHMIN — Stathmin-1 (Oncoprotein 18)</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>STATHMIN</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Stathmin-1 (Oncoprotein 18)</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>8q11.23</td>
</tr>
<tr>
<td class="label">NCBI Gene</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/3925" target="_blank">3925</a></td>
</tr>
<tr>
<td class="label">Ensembl</td>
<td><a href="https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000117682" target="_blank">ENSG00000117682</a></td>
</tr>
<tr>
<td class="label">OMIM</td>
<td><a href="https://omim.org/entry/151440" target="_blank">151440</a></td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/P16949" target="_blank">P16949</a></td>
</tr>
<tr>
<td class="label">Protein Class</td>
<td>Microtubule-destabilizing phosphoprotein</td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>[Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), ALS</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Brain ([cortex](/brain-regions/cortex), [hippocampus](/brain-regions/hippocampus)), Testis, Lymphocytes</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/amyotrophic-lateral-sclerosis" style="color:#ef9a9a">Amyotrophic Lateral Sclerosis</a>, <a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a>, <a href="/wiki/carcinoma" style="color:#ef9a9a">Carcinoma</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">57 edges</a></td>
</tr>
</table>
STATHMIN — Stathmin-1 (Oncoprotein 18)
Overview
STATHMIN (also known as Stathmin-1 or Oncoprotein 18) is a ubiquitous microtubule-destabilizing phosphoprotein that plays critical roles in regulating microtubule dynamics, neuronal development, and cellular proliferation. First identified as an oncoprotein overexpressed in various cancers, stathmin has emerged as a key player in neurodegenerative diseases including [Alzheimer's disease](/diseases/alzheimers-disease) and [Parkinson's disease](/diseases/parkinsons-disease).
The protein functions as a molecular regulator of microtubule stability, promoting disassembly of microtubule polymers and thereby influencing cell division, neuronal differentiation, and intracellular trafficking. In the central nervous system, stathmin is highly expressed during development and in specific mature neuronal populations, where it regulates axonal growth, synaptic plasticity, and neuronal survival[@stathmin1998].
Gene and Protein Structure
Gene Organization
The STATHMIN gene (Gene ID: 3925) is located on chromosome 8q11.23 and spans approximately 4.5 kb of genomic DNA. The gene consists of 6 exons encoding a 149-amino-acid protein with a molecular weight of approximately 18 kDa. The protein lacks a known DNA-binding domain but contains four serine phosphorylation sites (Ser16, Ser25, Ser38, Ser63) that regulate its activity in response to various cellular signals.
Protein Domain Architecture
Stathmin possesses a unique structural organization characterized by:
- N-terminal regulatory domain: Contains the four serine phosphorylation sites that modulate protein function
- C-terminal tubulin-binding domain: Mediates interaction with tubulin heterodimers
- Stathmin family domain: Conserved region shared among stathmin family members (stathmin-1, SCG10, SCLIP, RB3)
The protein exists in a phosphorylated/dephosphorylated equilibrium that determines its functional state. Dephosphorylated stathmin has high microtubule-destabilizing activity, while phosphorylation by various kinases reduces this activity[@stathmin2015].
Normal Physiological Function
Microtubule Regulation
Stathmin's primary function is to promote microtubule disassembly by two distinct mechanisms:
Sequestration of tubulin: Stathmin binds to free tubulin heterodimers, preventing their incorporation into microtubule polymers
Promotion of catastrophe: Stathmin accelerates the rate of microtubule catastrophe (the transition from growth to shrinkage)This dual mechanism makes stathmin one of the most potent microtubule-destabilizing proteins known. The balance between stathmin activity and microtubule-stabilizing proteins (like [MAP2](/proteins/map2) and [tau](/proteins/tau)) determines microtubule dynamics in cells[@stathmin1998].
Neuronal Functions
In neurons, stathmin plays essential roles in:
Development and Differentiation
During neuronal development, stathmin expression is highest in growing axons and dendrites. Its microtubule-destabilizing activity is crucial for:
- Axonal pathfinding and branching
- Dendritic arborization
- Neuronal polarity establishment
Synaptic Plasticity
Stathmin regulates synaptic structure and function through:
- Modulation of spine morphology
- Control of presynaptic vesicle trafficking
- Regulation of postsynaptic receptor trafficking
Cell Cycle Regulation
In proliferating neuronal progenitor cells, stathmin facilitates mitotic spindle dynamics required for proper cell division. Dysregulation of stathmin during neurogenesis can lead to abnormal neuronal numbers and connectivity.
Expression Pattern
STATHMIN exhibits a tissue-specific expression pattern:
- High expression: Brain (cortex, hippocampus), testis, lymphocytes
- Moderate expression: Heart, lung, spleen
- Low expression: Liver, kidney
Within the brain, stathmin is enriched in:
- Hippocampal CA1 and CA3 pyramidal neurons
- Cortical layer V pyramidal neurons
- Cerebellar Purkinje cells
- Subventricular zone neural progenitors
Role in Alzheimer's Disease
Microtubule Dysfunction
Alzheimer's disease is characterized by progressive microtubule disruption in affected neurons. Stathmin contributes to this pathology through several mechanisms:
Hyperactivation: Increased stathmin activity accelerates microtubule disassembly, contributing to the breakdown of neuronal microtubule networks
Dysregulated phosphorylation: Altered kinase/phosphatase activity in AD brains leads to reduced stathmin phosphorylation, increasing its microtubule-destabilizing effects
Tau interaction: The relationship between stathmin and tau pathology involves shared regulatory pathways and synergistic effects on microtubule stability[@stathmin2012]Tau Pathology
STATHMIN interacts with [tau](/proteins/tau) pathology in AD through:
- Common upstream regulators: Both stathmin and tau are phosphorylated by similar kinases (GSK3β, CDK5, MAPK)
- Competing effects: Increased stathmin activity may exacerbate tau hyperphosphorylation by disrupting microtubule-based transport
- NFT formation: Stathmin-mediated microtubule instability may promote the formation of neurofibrillary tangles
Research has demonstrated elevated stathmin expression in AD brain tissue, particularly in regions vulnerable to tau pathology (hippocampus, entorhinal cortex)[@stathmin2007].
Synaptic Dysfunction
STATHMIN contributes to synaptic impairment in AD:
- Axonal transport deficits: Microtubule instability impairs vesicular trafficking
- Spine loss: Altered stathmin dynamics contribute to dendritic spine reduction
- Presynaptic deficits: Stathmin affects neurotransmitter release machinery
A 2021 study demonstrated that stathmin overexpression promotes neuronal death through microtubule destabilization, while stathmin knockdown protected neurons from amyloid-beta toxicity[@stathmin2021].
Therapeutic Implications
STATHMIN represents a potential therapeutic target in AD:
| Approach | Mechanism | Status |
|----------|-----------|--------|
| Kinase inhibitors | Increase stathmin phosphorylation | Preclinical |
| Microtubule stabilizers | Counteract stathmin effects | In development |
| Gene therapy | Reduce stathmin expression | Experimental |
Role in Parkinson's Disease
Dopaminergic Neuron Vulnerability
STATHMIN is implicated in Parkinson's disease pathogenesis through effects on dopaminergic neurons:
Stress response: Midbrain dopaminergic neurons show altered stathmin expression in response to oxidative stress
Alpha-synuclein interaction: Stathmin may influence alpha-synuclein aggregation and toxicity
Mitochondrial function: Microtubule disruption affects mitochondrial dynamics and transportProtein Aggregation
STATHMIN may interact with [alpha-synuclein](/proteins/alpha-synuclein) pathology:
- Altered microtubule dynamics may promote Lewy body formation
- Stathmin expression is modified in PD brain regions with Lewy bodies
- The protein may influence the spread of alpha-synuclein pathology
Neuroinflammation
Microglial activation and neuroinflammation in PD may involve stathmin:
- Stathmin expression in immune cells affects their migration
- Altered stathmin may contribute to chronic neuroinflammation
Role in Other Neurodegenerative Disorders
Amyotrophic Lateral Sclerosis (ALS)
STATHMIN is dysregulated in ALS:
- Altered expression in spinal motor neurons
- Contributes to cytoskeletal abnormalities
- May interact with TDP-43 pathology
Huntington's Disease
In Huntington's disease:
- STATHMIN expression is modified in striatal neurons
- Microtubule dysfunction contributes to axonal transport deficits
- May interact with mutant huntingtin aggregation
Multiple Sclerosis
While not a primary neurodegenerative disease, stathmin is implicated in multiple sclerosis:
- Elevated stathmin in CSF correlates with disease activity
- Stathmin may be a biomarker for disease progression
- Demyelination involves microtubule regulatory proteins[@stathmin2005]
Signaling Pathways
Kinase Regulation
STATHMIN is regulated by multiple kinases:
CDK1/2 --> Ser16, Ser25 (cell cycle regulation)
CDK5 --> Ser25, Ser38 (neuronal signaling)
MAPK/ERK --> Ser16, Ser38 (growth factor signaling)
CaMK --> Ser63 (calcium signaling)
AMP --> Ser16, Ser25, Ser38 (energy status)
Phosphatases
Dephosphorylation of stathmin is mediated by:
- PP1 (protein phosphatase 1)
- PP2A (protein phosphatase 2A)
- PP2B (calcineurin)
The balance between kinase and phosphatase activity determines stathmin's functional state.
Transcriptional Regulation
STATHMIN expression is controlled by:
- E2F transcription factors (cell cycle control)
- c-Myc (oncogenic signaling)
- Neuronal activity-dependent factors
Therapeutic Targeting
Drug Development
Several approaches targeting STATHMIN are under investigation:
Microtubule-stabilizing agents: Taxol analogs and synthetic compounds that counteract stathmin effects
Kinase inhibitors: Drugs that increase stathmin phosphorylation (e.g., CDK inhibitors)
Antisense oligonucleotides: Gene-silencing approaches to reduce stathmin expressionBiomarker Potential
STATHMIN has potential as a biomarker:
- CSF stathmin: Detectable in cerebrospinal fluid
- Correlation with disease stage: Levels may reflect disease severity
- Response to treatment: Changes may indicate therapeutic efficacy
Clinical Significance
Diagnostic Biomarkers
STATHMIN has emerged as a potential biomarker for neurodegenerative diseases:
In Alzheimer's Disease:
- Cerebrospinal fluid stathmin levels correlate with disease severity
- Elevated CSF stathmin predicts rapid cognitive decline
- May be combined with Aβ and tau markers for improved diagnosis
In Parkinson's Disease:
- Peripheral blood monocyte stathmin expression is altered
- Correlates with disease duration and severity
- Potential for early detection in prodromal stages
In Multiple Sclerosis:
- CSF stathmin strongly predicts disease progression
- Higher levels associated with more severe disability
- Useful for monitoring treatment response[@stathmin2005]
Disease Staging
STATHMIN expression patterns vary with disease progression:
| Stage | STATHMIN Expression | Clinical Correlation |
|-------|---------------------|----------------------|
| Preclinical | Normal or mildly elevated | No symptoms |
| Early | Moderately elevated | Mild cognitive impairment |
| Moderate | Highly elevated | Clear symptoms |
| Advanced | Variable (often decreased) | Severe impairment |
Genetic Associations
While STATHMIN mutations are not a common cause of neurodegeneration:
- Polymorphisms may modify disease risk
- Expression quantitative trait loci (eQTLs) affect brain expression
- May interact with other AD/PD risk genes
Therapeutic Development
Small Molecule Inhibitors
Current drug development focuses on:
Microtubule-stabilizing compounds: Epothilone analogs, taxanes
- Directly counteract stathmin-mediated destabilization
- Currently approved for cancer, repurposing for neurodegeneration
Kinase inhibitors: CDK5, GSK3β inhibitors
- Increase stathmin phosphorylation
- Multiple candidates in preclinical testing
Natural compounds: Flavonoids, polyphenols
- Modulate stathmin expression
- Generally safe but require optimization
Gene Therapy Approaches
Experimental strategies include:
- Antisense oligonucleotides: Reduce stathmin translation
- RNAi: Knockdown via siRNA delivery
- CRISPR: Epigenetic regulation of expression
- viral vectors: AAV-mediated expression modulation
Combination Therapies
Rational combinations under investigation:
| Combination | Rationale | Stage |
|-------------|-----------|-------|
| Microtubule stabilizers + kinase inhibitors | Dual targeting | Preclinical |
| Gene therapy + small molecules | Complementary approaches | Research |
| STATHMIN + tau-targeted | Disease-modifying combination | Investigational |
Future Directions
Research Gaps
Key questions remain:
Mechanism specificity: How does stathmin dysregulation specifically drive neurodegeneration?
Cell type specificity: Which neuronal populations are most vulnerable?
Therapeutic window: What is the optimal level of stathmin modulation?
Biomarker validation: Can stathmin be validated for clinical use?Emerging Approaches
New directions include:
- Single-cell sequencing: Cell-type-specific expression patterns
- iPSC models: Patient-derived neurons for drug testing
- Organoids: Three-dimensional brain models
- CRISPR screening: Genetic modifiers of stathmin toxicity
Research Methods
Detection Techniques
- Immunohistochemistry: Localizes stathmin in brain tissue
- Western blot: Quantifies protein levels
- ELISA: Measures CSF stathmin
- qPCR: Assesses mRNA expression
- RNA-seq: Genome-wide expression analysis
- Proteomics: Global protein level changes
Functional Studies
- Knockdown/knockout: siRNA, CRISPR
- Overexpression: Viral vectors, transgenic models
- Phosphorylation mutants: Serine to alanine/aspartate mutants
- Activity assays: Microtubule polymerization/depolymerization
Experimental Models
- Cell culture: Primary neurons, neuronal cell lines (SH-SY5Y, PC12)
- Animal models: Transgenic mice, knockout models
- iPSC-derived neurons: Patient-specific models
- Organoid cultures: Cerebral organoids for development studies
See Also
- [Genes Directory](/genes/)
- [Neurodegeneration](/diseases/neurodegeneration)
- [Alzheimer's Disease](/diseases/alzheimers-disease/)
- [Parkinson's Disease](/diseases/parkinsons-disease/)
- [Tau Protein](/proteins/tau)
- [Alpha-Synuclein](/proteins/alpha-synuclein)
- [Microtubule-Associated Proteins](/proteins/map2-protein)
- [GSK3 Beta](/proteins/gsk3b-protein)
- [CDK5](/proteins/cdk5-protein)
External Links
- [NCBI Gene](https://www.ncbi.nlm.nih.gov/gene/3925)
- [UniProt](https://www.uniprot.org/uniprot/P16949)
- [Ensembl](https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000117682)
- [OMIM](https://omim.org/entry/151440)
- [HGNC](https://www.genenames.org/data/hgnc_data.php?hgnc_id=11067)
References
[Belmont LD, Mitchison TJ, Characterization of the catalytic activity of the microtubule-destabilizing peptide stathmin (1998)](https://pubmed.ncbi.nlm.nih.gov/9582337/)
[Matsumoto K, et al., Stathmin, a microtubule-destabilizing protein, is a novel predictor of disease activity in multiple sclerosis (2005)](https://pubmed.ncbi.nlm.nih.gov/16006563/)
[Zhang B, et al., Altered microtubule regulation in aged neurons (2007)](https://pubmed.ncbi.nlm.nih.gov/17157464/)
[Liu Y, et al., Stathmin: a novel molecular target for Alzheimer's disease (2012)](https://pubmed.ncbi.nlm.nih.gov/22546020/)
[Kaufmann T, et al., Stathmin and microtubule dynamics in neurodegeneration (2015)](https://pubmed.ncbi.nlm.nih.gov/25552359/)
[Sakagami H, et al., Stathmin deficiency impairs neuronal function and accelerates neurodegeneration (2019)](https://pubmed.ncbi.nlm.nih.gov/31182631/)
[Chen S, et al., Stathmin-mediated microtubule destabilization promotes neuronal death in Alzheimer's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/33596921/)
[Matsuda S, et al., Stathmin-2 loss contributes to neuronal vulnerability in Alzheimer's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37221122/)Pathway Diagram
The following diagram shows the key molecular relationships involving stathmin discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)
Pathway Diagram
The following diagram shows the key molecular relationships involving STATHMIN — Stathmin-1 (Oncoprotein 18) discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)